1.Male and female patients â?¥18 and â?¤65 years with active COVID-19 confirmed by RT-PCR, within less than 72 hours prior to randomization, <br/ >2.Participants with moderate to severe active COVID-19 (Clinical Management of COVID-19 Guidelines of MOHFW) at screening and baseline defined as: <br/ >a)Radiological evidence of pulmonary infiltrates or Clinical features such as dyspnea and/or hypoxia, fever, cough, AND <br/ >b)SpO2 of <93 % on room air AND <br/ >c)Respiratory rate of â?¥24 per minute <br/ >3.Women of childbearing potential agreeing to use of adequate contraception till study completion at a minimum 30 days until after the last dose of study intervention <br/ >4.Male participants are eligible if they agree to use contraception /barrier during sexual activities or donation of sperm for the purpose of reproduction PLUS, during the study and till 90 days completion of the study. <br/ >5.Participants who are willing to give the consent to particate in the trial. <br/ >

1.Male and female patients â?¥18 and â?¤65 years with active COVID-19 confirmed by RT-PCR, within less than 72 hours prior to randomization, <br/ >2.Participants with moderate to severe active COVID-19 (Clinical Management of COVID-19 Guidelines of MOHFW) at screening and baseline defined as: <br/ >a)Radiological evidence of pulmonary infiltrates or Clinical features such as dyspnea and/or hypoxia, fever, cough, AND <br/ >b)SpO2 of <93 % on room air AND <br/ >c)Respiratory rate of â?¥24 per minute <br/ >3.Women of childbearing potential agreeing to use of adequate contraception till study completion at a minimum 30 days until after the last dose of study intervention <br/ >4.Male participants are eligible if they agree to use contraception /barrier during sexual activities or donation of sperm for the purpose of reproduction PLUS, during the study and till 90 days completion of the study. <br/ >5.Participants who are willing to give the consent to particate in the trial. <br/ >

1.Male and female patients â?¥18 and â?¤65 years with active COVID-19 confirmed by RT-PCR, within less than 72 hours prior to randomization, <br/ >2.Participants with moderate to severe active COVID-19 (Clinical Management of COVID-19 Guidelines of MOHFW) at screening and baseline defined as: <br/ >a)Radiological evidence of pulmonary infiltrates or Clinical features such as dyspnea and/or hypoxia, fever, cough, AND <br/ >b)SpO2 of <93 % on room air AND <br/ >c)Respiratory rate of â?¥24 per minute <br/ >3.Women of childbearing potential agreeing to use of adequate contraception till study completion at a minimum 30 days until after the last dose of study intervention <br/ >4.Male participants are eligible if they agree to use contraception /barrier during sexual activities or donation of sperm for the purpose of reproduction PLUS, during the study and till 90 days completion of the study. <br/ >5.Participants who are willing to give the consent to particate in the trial. <br/ >

1.Male and female patients â?¥18 and â?¤65 years with active COVID-19 confirmed by RT-PCR, within less than 72 hours prior to randomization, <br/ >2.Participants with moderate to severe active COVID-19 (Clinical Management of COVID-19 Guidelines of MOHFW) at screening and baseline defined as: <br/ >a)Radiological evidence of pulmonary infiltrates or Clinical features such as dyspnea and/or hypoxia, fever, cough, AND <br/ >b)SpO2 of <93 % on room air AND <br/ >c)Respiratory rate of â?¥24 per minute <br/ >3.Women of childbearing potential agreeing to use of adequate contraception till study completion at a minimum 30 days until after the last dose of study intervention <br/ >4.Male participants are eligible if they agree to use contraception /barrier during sexual activities or donation of sperm for the purpose of reproduction PLUS, during the study and till 90 days completion of the study. <br/ >5.Participants who are willing to give the consent to particate in the trial. <br/ >